Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

European journal of clinical pharmacology - 1 Nov 2011

Chianella Caterina, Gragnaniello Daniela, Maisano Delser Pierpaolo, Visentini Maria Francesca, Sette Elisabetta, Tola Maria Rosaria, Barbujani Guido, Fuselli Silvia

Abstract excerpt

PURPOSE: Cholinesterase inhibitors are commonly prescribed to patients with Alzheimer's disease (AD) to enhance cholinergic neurotransmission. Differential response to these treatments has been observed, and claims have been made that individual genetic variants may influence the pharmacokinetic and pharmacodynamic properties of these drugs. Here we assess the effects of genetic variation at two loci involved in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Butyrylcholinesterase

Share to Cholinesterase Inhibitors

Share to Cognition

Share to Cytochrome P-450 CYP2D6

Share to Indans

Share to Piperidines

Source

Identifiers

PMID: 21630031
DOI: 10.1007/s00228-011-1064-x

Genes

BCHE
APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.PMID 21630031Read ↗

Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease PharmacogeneticsSemantic proximity Read ↗

Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.Semantic proximity Read ↗

Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.Semantic proximity Read ↗

Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Effect of genetic polymorphisms on Alzheimer’s disease treatment outcomes: an updateSemantic proximity Read ↗

Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.Semantic proximity Read ↗

Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease PatientsSemantic proximity Read ↗

Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil.Semantic proximity Read ↗

Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.Semantic proximity Read ↗

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.